立体定向放疗治疗非小细胞肺癌的α/β比值估计
该研究合并两个大样本回顾性数据集,共纳入1294例早期非小细胞肺癌的立体定向放疗(≤10次),基于局部复发数并校正肿瘤大小,用Cox回归、logistic肿瘤控制概率模型和贝叶斯治愈率模型估计α/β比值。三种方法最佳拟合估计分别为12.8 Gy、14.9 Gy和12–16 Gy(取决于α/β先验),不确定性较大,未能排除常规α/β=10 Gy。
要点
- 合并1294例早期NSCLC的SBRT(≤10次)数据,中位随访17.7个月观察到109例局部进展。
- Cox回归、3年肿瘤控制概率logistic模型和治愈率模型估计α/β分别为12.8 Gy、14.9 Gy和12–16 Gy。
- 估计不确定性较大,未能排除常规α/β=10 Gy,临床可继续用LQ形式比较SBRT方案。
核心结论
- 临床医生可继续使用简单LQ形式比较NSCLC不同SBRT治疗方案。
- 本研究数据未排除α/β=10 Gy,但12–16 Gy的较大值更可能,与近期meta回归分析一致。
研究设计与样本
- 合并两个大型回顾性数据集,共1294例早期NSCLC的SBRT(≤10次)。
- 采用Cox比例风险回归、logistic肿瘤控制概率模型和生物学驱动的贝叶斯治愈率模型估计α/β比值。
- 基于观察到的局部复发数并校正肿瘤大小进行估计。
主要发现
- 中位17.7个月(范围0.6–76.3个月)随访中共观察到109例局部进展。
- Cox回归最佳拟合估计α/β=12.8 Gy。
- 3年肿瘤控制概率logistic回归最佳拟合估计α/β=14.9 Gy。
- 治愈率模型最佳拟合估计α/β=12–16 Gy(取决于α/β先验)。
- 各估计不确定性较大,未能排除常规α/β=10 Gy。
关键数值与推荐
- Cox回归估计α/β=12.8 Gy。
- 3年肿瘤控制概率logistic回归估计α/β=14.9 Gy。
- 治愈率模型估计α/β=12–16 Gy(取决于α/β先验)。
- 常规假设α/β=10 Gy未被数据排除。
临床怎么用
- 比较NSCLC不同SBRT分割方案时,可继续使用简单LQ形式。
- 若需考虑α/β不确定性,12–16 Gy范围较10 Gy更可能,但证据不确定性大。
局限性
- α/β估计不确定性较大,未能排除常规α/β=10 Gy。
- 研究基于回顾性数据集合并,可能受数据异质性影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-dose hypofractionated radiotherapy should theoretically result in a deviation from the typical linear-quadratic shape of the cell survival curve beyond a certain threshold dose, yet no evidence for this hypothesis has so far been found in clinical data of stereotactic body radiotherapy treatment (SBRT) for early-stage non-small cell lung cancer (NSCLC). A pragmatic explanation is a larger α/β ratio than the conventionally assumed 10 Gy. We here attempted an estimation of the α/β ratio for NSCLC treated with SBRT using individual patient data. MATERIALS AND METHODS: We combined two large retrospective datasets, yielding 1294 SBRTs (≤10 fractions) of early stage NSCLC. Cox proportional hazards regression, a logistic tumor control probability model and a biologically motivated Bayesian cure rate model were used to estimate the α/β ratio based on the observed number of local recurrences and accounting for tumor size. RESULTS: A total of 109 local progressions were observed after a median of 17.7 months (range 0.6-76.3 months). Cox regression, logistic regression of 3 year tumor control probability and the cure rate model yielded best-fit estimates of α/β = 12.8 Gy, 14.9 Gy and 12-16 Gy (depending on the prior for α/β), respectively, although with large uncertainties that did not rule out the conventional α/β = 10 Gy. CONCLUSIONS: Clinicians can continue to use the simple LQ formalism to compare different SBRT treatment schedules for NSCLC. While α/β = 10 Gy is not ruled out by our data, larger values in the range 12-16 Gy are more probable, consistent with recent meta-regression analyses.
引用
- Klement RJ, Sonke JJ, Allgäuer M, et al. Estimation of the α/β ratio of non-small cell lung cancer treated with stereotactic body radiotherapy. Radiother Oncol. 2019. PMID: 31431371. doi:10.1016/j.radonc.2019.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。